Stock Track | Sarepta Therapeutics Plunges 5.11% in Pre-market on Earnings Miss, CEO Retirement

Stock Track

Feb 26

Sarepta Therapeutics' stock plummeted 5.11% during pre-market trading on Thursday, as investors reacted negatively to the company's disappointing quarterly results and unexpected leadership transition announcement.

The biopharmaceutical company reported an adjusted loss of $3.58 per share for the fourth quarter of 2025, significantly missing analyst expectations of a $1.31 loss. While sales of $442.93 million exceeded consensus estimates, they still represented a 33% year-over-year decline, primarily due to reduced revenue from its Elevidys gene therapy following a voluntary shipment pause.

Adding to investor concerns, CEO Douglas Ingram announced plans to retire by the end of 2026 or upon the appointment of his successor, creating uncertainty about the company's future leadership during a challenging period. The news follows a tumultuous year for Sarepta marked by clinical setbacks, regulatory challenges, and job cuts. Analyst firm Baird further pressured the stock by cutting its price target to $20 from $22, reflecting concerns about the company's near-term prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1101306032"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1101306032\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1101306032?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 20:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101306032","market":"us","top_or_hot":-1,"title":"Stock Track | Sarepta Therapeutics Plunges 5.11% in Pre-market on Earnings Miss, CEO Retirement","media":"Stock Track","content":"<p>Sarepta Therapeutics' stock plummeted 5.11% during pre-market trading on Thursday, as investors reacted negatively to the company's disappointing quarterly results and unexpected leadership transition announcement.</p><p>The biopharmaceutical company reported an adjusted loss of $3.58 per share for the fourth quarter of 2025, significantly missing analyst expectations of a $1.31 loss. While sales of $442.93 million exceeded consensus estimates, they still represented a 33% year-over-year decline, primarily due to reduced revenue from its Elevidys gene therapy following a voluntary shipment pause.</p><p>Adding to investor concerns, CEO Douglas Ingram announced plans to retire by the end of 2026 or upon the appointment of his successor, creating uncertainty about the company's future leadership during a challenging period. The news follows a tumultuous year for Sarepta marked by clinical setbacks, regulatory challenges, and job cuts. Analyst firm Baird further pressured the stock by cutting its price target to $20 from $22, reflecting concerns about the company's near-term prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Sarepta Therapeutics Plunges 5.11% in Pre-market on Earnings Miss, CEO Retirement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Sarepta Therapeutics Plunges 5.11% in Pre-market on Earnings Miss, CEO Retirement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-26 20:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sarepta Therapeutics' stock plummeted 5.11% during pre-market trading on Thursday, as investors reacted negatively to the company's disappointing quarterly results and unexpected leadership transition announcement.</p><p>The biopharmaceutical company reported an adjusted loss of $3.58 per share for the fourth quarter of 2025, significantly missing analyst expectations of a $1.31 loss. While sales of $442.93 million exceeded consensus estimates, they still represented a 33% year-over-year decline, primarily due to reduced revenue from its Elevidys gene therapy following a voluntary shipment pause.</p><p>Adding to investor concerns, CEO Douglas Ingram announced plans to retire by the end of 2026 or upon the appointment of his successor, creating uncertainty about the company's future leadership during a challenging period. The news follows a tumultuous year for Sarepta marked by clinical setbacks, regulatory challenges, and job cuts. Analyst firm Baird further pressured the stock by cutting its price target to $20 from $22, reflecting concerns about the company's near-term prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SRPT","symbol_name":"Sarepta Therapeutics","start_time":0,"source_url":"","article_id":"1101306032","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101306032","pubTimestamp":1772107658,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Sarepta Therapeutics' stock plummeted 5.11% during pre-market trading on Thursday, as investors reacted negatively to the company's disappointing quarterly results and unexpected leadership...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SRPT":"Sarepta Therapeutics"},"translate_title":"个股追踪|Sarepta Therapeutics盘前暴跌5.11%因盈利未达预期、CEO退休","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRPT":1},"content_text":"Sarepta Therapeutics' stock plummeted 5.11% during pre-market trading on Thursday, as investors reacted negatively to the company's disappointing quarterly results and unexpected leadership transition announcement.The biopharmaceutical company reported an adjusted loss of $3.58 per share for the fourth quarter of 2025, significantly missing analyst expectations of a $1.31 loss. While sales of $442.93 million exceeded consensus estimates, they still represented a 33% year-over-year decline, primarily due to reduced revenue from its Elevidys gene therapy following a voluntary shipment pause.Adding to investor concerns, CEO Douglas Ingram announced plans to retire by the end of 2026 or upon the appointment of his successor, creating uncertainty about the company's future leadership during a challenging period. The news follows a tumultuous year for Sarepta marked by clinical setbacks, regulatory challenges, and job cuts. Analyst firm Baird further pressured the stock by cutting its price target to $20 from $22, reflecting concerns about the company's near-term prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}